Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Kidney Disease: Improving Global Outcomes (KDIGO)

2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD)

, one of the most widely used global resources for CKD evaluation and management.

The update will focus on Chapter 3, “Delaying CKD progression and managing its complications,” with particular emphasis on medical management using newer therapies in light of the evolving therapeutic landscape.

At the time the 2024 guideline was published, recommendations for therapies such as ACE inhibitors, ARBs, SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRAs were based on the best available evidence, primarily in patients with diabetes or significant albuminuria, where most trial data were available. The guidance used a cautious, stepwise approach to balance potential benefits with safety considerations, including hyperkalemia and changes in kidney function. 

Since then, emerging trial data have demonstrated broader kidney and cardiovascular benefits of these therapies, including in people without diabetes, prompting KDIGO to initiate a focused update to ensure recommendations reflect the most current evidence.

“Since the publication of the 2024 KDIGO CKD Guideline, new data continue to emerge that have important implications for how we slow CKD progression and manage complications,” said Adeera Levin, MD, co-chair of the 2024 guidelines. “This focused update will ensure that KDIGO recommendations reflect the latest evidence and continue to support healthcare professionals caring for people living with CKD.”

These data include several therapies, which have been changing CKD management, including sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 (GLP-1)-based therapies, and nonsteroidal mineralocorticoid receptor antagonists (nsMRAs) in people with CKD without diabetes.

The update will follow the rigorous KDIGO guideline development methodology, including systematic evidence review and multidisciplinary expert input. Updated systematic evidence reviews will inform the decision to update existing recommendations and practice points. Levin is on board for the new update process, along with the original co-chair, Paul Stevens, MB, and a majority of the 2024 CKD Guideline Work Group, in order to ensure continuity and expertise.

“New cardiovascular and kidney outcomes trial data for SGLT2 inhibitors, GLP-1-based therapies, and nonsteroidal MRAs are raising important questions about how these therapies should be used in people with CKD who do not have diabetes,” said Stevens. “Our goal is to carefully review this evolving evidence and provide clear, practical guidance for healthcare professionals around the world.”

Kidney Disease: Defining Global Outcomes (KDIGO). CKD Evaluation and Management – KDIGO. KDIGO. Published 2024. Accessed March 17, 2026. 

https://kdigo.org/guidelines/ckd-evaluation-and-management/

Babitt JL, Berns JS, Bozkurt B, et al. Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD). 

https://doi.org/10.1016/j.kint.2025.06.005

Articles

KDIGO has initiated a focused update to the 2024 CKD Clinical Practice Guideline, targeting Chapter 3 on delaying progression and managing complications. The update is driven by emerging cardiovascular and kidney outcomes data extending benefits of cornerstone pharmacotherapies beyond the original evidence base centered on diabetes and/or significant albuminuria. KDIGO aims to recalibrate prior stepwise recommendations for ACEi/ARB, SGLT2 inhibitors, GLP-1–based therapies, and nonsteroidal MRAs, balancing efficacy with safety concerns such as hyperkalemia and acute eGFR changes through a rigorous evidence-review process.

KDIGO Launches Focused Update to 2024 CKD Guideline on Emerging Therapies


Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Chronic Kidney Disease

Strategic Alliance Partnership

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

KDIGO Launches Focused Update to 2024 CKD Guideline on Emerging Therapies

Expanding Use of Lower-Quality Kidneys Could Boost Transplants, Improve Equity, With Matthew Kaufmann, PhD

Allocating lower but acceptable quality kidneys to high-risk patients could introduce equity, along with shortened waiting times for underrepresented patient populations, according to new research.

cost-effective nature of having transplant centers utilize lower quality kidneys for adults ≥65 years of age

, especially when assessing the effects of increasing transplant rates by 25%.

“Hispanic and Black patients have longer than average wait times, and we found that increasing the rate of transplantation for all patients provides even greater health benefits for patients who have historically longer wait times,” said Matthew Kaufmann, PhD, Midwest Analytics and Disease Modeling Center Postdoctoral Fellow. “Therefore, we estimate that it would improve health equity.”

Within the US allocation system, approximately 20% of deceased donor kidneys are discarded each year. Specifically, >50% of those with a KDPI > 85 are discarded. In most clinical cases, when compared with staying on dialysis, even a KDPI = 99 kidney is suggested to offer improved longevity to transplant candidates.

To address this gap, investigators selected a synthetic cohort of adult candidates ≥ 65 years of age with end-stage kidney disease (ESKD) on the transplant waiting list, a patient population with markedly reduced rates of transplants compared to those <65 years of age.

“We believe there are clear benefits to honoring patient preferences—not just for older candidates, but also for patients with lower expected post-transplant survival and poorer outcomes on dialysis or the waitlist. We initially thought lower—but still acceptable—quality kidneys might offer limited benefit in this population. However, our findings show the opposite: these patients can derive substantial benefit, and this approach can be cost-effective. Ultimately, any patient who prioritizes shorter wait times and is willing to accept the risks of lower-quality kidneys should have access to them.”

Clinically, investigators found an association between deceased donor transplantation rate with a substantially decreased deaths on the waiting list and decreased waiting list removals as well as increased total net number of people undergoing transplants. Additionally, using lower-quality donor kidneys was associated with an increased risk of delayed graft function (DGF), but reduced wait times were associated with a decrease in this risk.

At a 5% increase in transplant rate, the DGF rate increased from the status quo. However, as the rate increased to 25%, the DGF rate moved back toward the status quo because of offsetting risk factors, a recurring pattern for the graft failure rate. Although lower kidney quality was associated with an increased risk of graft failure, reduced pretransplant dialysis time had a protective association.

The scenario analysis revealed that even if as many as 20% of transplanted kidneys were of lower quality than their given KDPI, increasing the transplantation rate by 25% would still be associated with 141 (range, 118-161) averted waiting list deaths and 375 (range, 350-396) waiting list removals per 10,000 candidates and 175 (range, 25-385) additional DGF cases and 103 (range, 9-266) additional graft loss events per 10,000 recipients.

Economically, when transplantation rates were increased by 25%, investigators noted an improvement in HRQOL cost-effectively, along with the most QALYs and lowest costs.

From the health care sector perspective, this would cost $8100 (95% credible interval [CrI], $700 to $141,00) per QALY gained. Notably, smaller increments of increased transplant rates cost more per QALY gained. Investigators believe smaller increases would mean fewer people undergo transplants, along with an increased mean time to transplant, which can result in additional adverse outcomes and costs.

Compared with the status quo, investigators observed a gain of 0.56 QALYs (95% CrI, 0.35 to 0.90 QALYs) and savings of $10,200 (95% CrI, $3400 to $17,900) for older adults.

Even for individuals ≥ 75 years of age, increasing deceased donor transplants by 25% was associated with HRQOL gains and cost $7800 (95% CrI, $1300 to $14,500) per QALY gained.

At a WTP threshold of $100,000 per QALY gained, choosing the status quo as opposed to the 25% increase transplantation rate was predicted to result in an expected loss of $51,400 per person, for a total of $886 million, from the health care sector perspective, and $58,300 per person, for a total of $1 billion, from the modified health care sector perspective.

While the study did not consider the downstream effects of new policies on younger candidates, investigators noted they would expect to see younger candidates benefit from shorter waiting times for all candidates.

Editor’s Note: Kaufmann reports no relevant disclosures.

Kaufmann MB, Tan JC, Owens DK, Chertow GM, Goldhaber-Fiebert JD. Cost-Effectiveness of Acceptable-Quality Deceased Donor Kidneys for Transplant in Older Candidates. 

https://doi.org/10.1001/jamanetworkopen.2025.55428

Kaufmann M. Using Lower Quality Kidneys to Reduce Costs, Increase Transplants for Older Adults, With Matthew Kaufmann, PhD. HCPLive. Published March 9, 2026. Accessed March 17, 2026. 

https://www.hcplive.com/view/using-lower-quality-kidneys-to-reduce-costs-and-increase-transplants-for-older-adults

Friedewald JJ, Schantz K, Mehrotra S. Kidney organ allocation: reducing discards. 

https://doi.org/10.1097/mot.0000000000001049

Videos

Allocating lower but acceptable quality kidneys to high-risk patients could introduce equity. 

Natasha Mesinkovska, MD, PhD, is a dermatologist and researcher at the University of California, Irvine School of Medicine Department of Dermatology.

Resilience, Rejection, and Recognition in Academic Dermatology

, dermatologist Natasha Mesinkovska, MD, PhD, reflects on career development, mentorship, and communication style, offering several practical insights relevant to clinicians navigating academic medicine.

Mesinkovska emphasizes the importance of proactively seeking opportunities early in one’s career. She describes a willingness to “ask for anything,” even offering to perform logistical tasks simply to gain exposure to academic meetings and professional environments. This mindset, prioritizing access and experience over prestige or compensation, ultimately facilitated speaking opportunities and career advancement. Her experience underscores a key principle: visibility and initiative often precede recognition. For clinicians, particularly early-career physicians and trainees, explicitly expressing interest in roles or opportunities may significantly increase the likelihood of inclusion.

Importantly, Mesinkovska acknowledges that self-advocacy does not always come naturally. She notes a personal discomfort with advocating for herself, contrasting this with her strong advocacy for mentees. This dichotomy highlights a common challenge among clinicians, especially women, who may hesitate to promote their own accomplishments or request opportunities. Nevertheless, she identifies “asking” as a foundational rule in mentorship, emphasizing that rejection is both common and necessary. She contextualizes success as a numbers game, numerous rejections accompany each acceptance, whether for publications, presentations, or awards. This normalization of rejection reframes it as an expected component of academic progression rather than a deterrent.

Mentorship emerges as another central theme. Mesinkovska describes a deliberate effort to “pay forward” the opportunities she received by supporting junior colleagues. She actively promotes mentees’ achievements and views their success as a shared accomplishment. This approach aligns with best practices in academic medicine, where sponsorship, actively advocating for trainees and junior faculty, can be as impactful as traditional mentorship. Her comments also suggest that fostering a supportive team culture requires intentional recognition of contributions, even for high-performing individuals who may otherwise go unnoticed.

The discussion also explores Mesinkovska’s approach to medical education and lecturing. She attributes her distinctive presentation style to a strong foundation in basic science (as a PhD-trained physician) combined with an emphasis on simplification and audience engagement. Her ability to translate complex scientific concepts into accessible, memorable content reflects experience in patient-facing scientific communication. She notes that preparing a single lecture may require 20–30 hours, highlighting the substantial effort behind effective teaching. This serves as a reminder that high-quality educational delivery is a skill requiring both time investment and deliberate practice.

Finally, Mesinkovska touches on the importance of valuing intellectual property in academic work. Initially sharing her materials freely, she later recognized the need to protect the significant effort involved in content creation. This perspective may resonate with clinicians increasingly contributing to educational and digital platforms.

Overall, the segment reinforces several actionable themes for clinicians: proactively seek opportunities, normalize rejection, invest in mentorship and sponsorship, prioritize clarity in communication, and recognize the value of one’s academic contributions.

Editor’s note: This episode was produced with the help of AI tools.

This segment of the latest episode of The Medical Sisterhood highlights insights into the career of Natasha Mesinkovska, MD, PhD.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Nicole Ramsey, MD, PhD, assistant professor of pediatrics in the division of pediatric allergy and immunology at the Icahn School of Medicine at Mount Sinai.

 Race-Neutral Spirometry Gains Support as Standard Practice, With Nicole Ramsey, MD, PhD

Updated guidance on lung function testing has prompted growing discussion around 

2026 American Academy of Allergy, Asthma & Immunology (AAAAI) 

annual meeting in Philadelphia, Nicole Ramsey, MD, PhD, assistant professor of pediatric allergy and immunology at the Icahn School of Medicine at Mount Sinai, discussed the rationale for race-neutral equations for spirometry and their potential clinical impact.

, Ramsey described a study in which surgeons evaluated a hypothetical patient and recommended lobectomy based on spirometry values calculated using either race-neutral or race-specific equations.

“It showed that surgeons would be less likely to do surgery on patients…if they're using the race-neutral and more likely to do it if they're using the race-specific. It's actually a counterargument using race-neutral equations,” Ramsey said. “However, it's possible that those people [who] would be less likely to do surgery on have worse outcomes. We don't know, but it's just because they have poor lung function that they’re less they're less excited to do surgery on someone because the numbers suggest that they might not have a good outcome.”

Spirometry is a fundamental tool used to evaluate lung function and diagnose conditions such as asthma and chronic obstructive pulmonary disease. Historically, interpretation of spirometry results relied on race-specific reference equations, which adjusted predicted lung function values based on a patient’s racial category. Earlier models, including the 1999 reference equations, required clinicians to modify raw spirometry values differently for patients identified as Black, White, or Mexican American.

Ramsey explained that these adjustments were originally based on the assumption that biological differences between racial groups influenced lung capacity. However, emerging evidence suggests that environmental exposures and social determinants of health, rather than race itself, better explain differences observed in lung function across populations.

She noted that historical environmental inequities likely contributed to early observations that shaped race-based equations. For example, greater exposure to industrial pollution and occupational hazards among Black populations during earlier decades may have influenced lung function measurements used in historical datasets.

Professional societies have begun responding to this evolving evidence base. The American Thoracic Society now recommends using race-neutral spirometry equations, including updated reference values introduced through the Global Lung Function Initiative’s 2022 model. These equations incorporate data from diverse populations without applying race-specific correction factors.

Despite these recommendations, adoption has not yet been universal. Ramsey noted that practical barriers, such as outdated spirometry equipment and software, may slow implementation. Many older spirometers cannot easily integrate newer reference equations, meaning clinics may need to upgrade hardware or software to transition fully.

Beyond clinical care, changes in spirometry interpretation could have broader societal implications. Ramsey highlighted that algorithms used in areas such as life insurance underwriting may interpret lung function differently depending on whether race-based adjustments are applied.

Ramsey emphasized that race-neutral spirometry represents a step toward more accurate and equitable lung health assessment, though continued research will be needed to refine predictive tools.

“We need better risk calculators to take people's whole [clinical context] into account, not just their race, not just their height, but other things that they might be exposed to that might be contributing to their lung health,” Ramsey said. “We need additional studies, and we need different predictors, potentially using AI or other advanced statistical tools, to help us interpret our spirometry results.”

ALK-Abello, Inc., and Genentech USA, Inc.

Ramsey, N. Using Race-Neutral Spirometry Equations Improves Diagnostic Accuracy. Session presented at the 2026 American Academy of Allergy, Asthma, & Immunology in Philadelphia on March 2, 2026.

At AAAAI 2026, Ramsey discussed the shift toward race-neutral spirometry equations, their clinical implications, and barriers to widespread adoption.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Lung Cancer

Race-Neutral Spirometry Gains Support as Standard Practice, With Nicole Ramsey, MD, PhD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Image Credit: US Food and Drug Administration

The US Food and Drug Administration has issued a Complete Response Letter (CRL) to Aldeyra Therapeutics’ New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. 

As described in a March 17, 2026, release from the Company, the CRL stated that there is “a lack of substantial evidence consisting of adequate and well-controlled investigations … that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling” and that “the application has failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease.” The letter also stated that the “inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings” and that the “totality of evidence from the completed clinical trials does not support the effectiveness of the product.” Consistent with prior NDA reviews of reproxalap, no safety or manufacturing concerns were identified.

“To the thousands of American and Canadian patients who participated in our clinical trials and to the tens of millions of patients with dry eye disease worldwide, I want to assure you that we will work with urgency to support the FDA in enabling market access to what is, to our knowledge, the only drug with clinical activity within minutes of administration in patients with dry eye disease, a condition that is today treated with medications that require weeks or months of treatment to achieve even modest improvement,” stated Todd Brady, MD, PhD, President and Chief Executive Officer of Aldeyra.

Aldeyra first submitted an NDA for reproxalap in early 2023; they received a CRL on November 16, 2023, which stated that the NDA did not exhibit “efficacy in treating ocular symptoms associated with dry eyes” as defined by the FDA. Aldeyra announced the resubmission of the NDA on October 3, 2024. After another CRL in April of 2025, Aldeyra conducted an additional dry eye chamber trial, supplementing the NDA with these data in June of 2025.

The latest NDA was supported by results from both the ALLEVIATE trial, a Phase 3 randomized, double-masked, vehicle-controlled clinical trial which achieved its primary endpoint in August of 2024, and the more recent dry eye chamber trial, requested after the FDA administered another CRL in April of 2025. According to Aldeyra, the ALLEVIATE trial indicated the superiority of reproxalap over vehicle in treating ocular discomfort (

 = .004), which is an FDA accepted symptom of dry eye disease.

During the trial, participants were administered vehicle – the drug product sans active ingredient – before and during exposure to a dry eye chamber. The 132 qualifying patients were then randomized to either another dose of vehicle or reproxalap before and during exposure to another dry eye chamber. 66 patients received vehicle and 66 received reproxalap. The primary endpoint of the trial was ocular discomfort from 80-100 minutes of exposure to the chamber.

Investigators reported no safety signals observed during the trial, and reproxalap was well tolerated by the participants. The most reported adverse event was, according to Aldeyra, mild and transient instillation site discomfort, which was consistent with prior trials.

In May of 2025, Aldeyra announced the completion of the dry eye chamber trial, which demonstrated reproxalap’s capacity to reduce ocular discomfort. No notable differences in baseline scores were noted across treatment arms during this trial, and no safety concerns were identified. As with prior trials, the most common adverse event was mild and transient installation site discomfort, rarely lasting longer than 1 minute.

In the latest CRL, the FDA recommended that the reasons for failure in certain trials be explored, and that populations or certain conditions in which reproxalap may be effective be identified. The Agency did not recommend conducting additional trials or request submission of additional confirmatory evidence.

In the press release, Aldeyra indicated it does not currently expect to pursue additional clinical trials and intends to expeditiously request a Type A meeting to understand the actions needed for NDA approval. Per Prescription Drug User Fee Act (PDUFA) goals, the target Type A meeting date is within 30 days of receipt of the meeting request.

Aldeyra Therapeutics. Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease. March 17, 2026. Accessed March 17, 2026. 

https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-receives-complete-response-letter-us-food-1

Clark D, Cavanagh B, Shields AL, Karpecki P, Sheppard J, Brady TC. Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial. 

Aldeyra Therapeutics, Inc. Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease. November 27, 2023. Accessed April 1, 2025. 

https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-receives-complete-response-letter-us-food

Aldeyra Therapeutics, Inc. Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease. October 3, 2024. Accessed April 1, 2025. 

https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-resubmits-reproxalap-new-drug-application

Aldeyra Therapeutics, Inc. Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap. August 8, 2024. Accessed April 1, 2025. 

https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-achieves-primary-endpoint-phase-3-dry-eye

Aldeyra Therapeutics, Inc. Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease. June 17, 2025. Accessed March 13, 2026. 

https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-resubmits-reproxalap-new-drug-application-0

The FDA issued a Complete Response Letter for reproxalap’s NDA in dry eye disease, citing insufficient substantial evidence from adequate, well-controlled studies and inconsistent efficacy findings across the program. No safety or manufacturing deficiencies were identified, aligning with prior reviews. Supportive data included a Phase 3 randomized, double-masked, vehicle-controlled trial meeting a symptom endpoint for ocular discomfort and a subsequent dry eye chamber study showing reduced discomfort with favorable tolerability. The Agency advised root-cause exploration and responder population identification.

The FDA has issued its third CRL to topical ocular reproxalap for the treatment of signs and symptoms of dry eye disease.

FDA News

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

FDA Issues Third Reproxalap CRL for Dry Eye Disease

Martinez and Harper outline practical workflows for initiating and titrating cardiac myosin inhibitors, emphasizing multidisciplinary team structure, telemedicine, and logistics around REMS and imaging.

Video Series

Implementing Cardiac Myosin Inhibitors in oHCM: Workflow and Team-Based Care

Martinez and Harper describe a hub-and-spoke model for HCM care, follow-up cadence, and a structured “4-pillar” framework for longitudinal management, including imaging, biomarkers, and family-based risk strategies.



Comprehensive oHCM Follow-up: Hub-and-Spoke Care and 4-Pillar Framework

Martinez and Harper review real-world REMS data on cardiac myosin inhibitors, refine approaches to safety monitoring, and question how frequently echocardiography is truly needed in stable oHCM patients.

Long-term Safety, REMS Data, and Echo Monitoring for oHCM Therapies

Corey Cavanaugh, DO, is an academic nephrologist at the Cleveland Clinic. 

Even Routine Urinalysis Can Reveal Hidden IgA Nephropathy, Especially in Young Adults

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Even Routine Urinalysis Can Reveal Hidden IgAN In Young Patients, With Corey Cavanaugh, DO

Viet Le, DMSc, PA-C, is a preventive cardiology PA at Intermountain Health and the former president of the Academy of Physician Associates in Cardiology.

Le discusses the AHA/ACC clinical guidelines for the management of dyslipidemia, highlighting PREVENT and a renewed focus on Lp(a).

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

ACC/AHA Dyslipidemia Guidelines Focus on PREVENT, Lp(a), With Viet Le, DMSc, PA-C

Emily McDonald, MD, MSc, is an associate professor of medicine at McGill University.

McDonald discusses new trial data suggesting an initial vancomycin taper may reduce early recurrence of C difficile infection.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

C Difficile Infection

C. difficile condition center page, resources on the topics of medical news and expert insight into Clostridium difficile can be found. Content includes articles, interviews, videos, podcasts, and breaking news on C. diff research, treatment, and drug development.

Vancomycin Taper Strategies to Prevent C Difficile Recurrence, With Emily McDonald, MD, MSc

This segment of Eichenfield's interview highlights long-term safety findings on roflumilast cream .05% for children 2 - 5 years old with atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Long-Term Safety of Roflumilast Cream for Children, With Lawrence Eichenfield, MD

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

New data show tegoprubart enabled insulin independence and strong glycemic control in adults with long-standing type 1 diabetes undergoing islet transplantation.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

Tegoprubart Enables Insulin Independence in Type 1 Diabetes Islet Transplant Study

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

Allergy experts weigh ruxolitinib, tapinarof, and roflumilast—new nonsteroidal creams that reshape atopic dermatitis care beyond steroids.

From First Flare to Treatment-Free Intervals: Prescribing Nonsteroidal Topicals for Atopic Dermatitis

Kathryn Berlacher, MD, MS, is the clinical & strategic director of cardiology at UPMC and the chair of ACC 2026.

This conference preview with Kathryn Berlacher, MD, MS, and Kristen Campbell, PharmD, highlights the top 6 trials to watch at ACC 2026.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Latest News

KDIGO Launches Focused Update to 2024 CKD Guideline on Emerging Therapies

Expanding Use of Lower-Quality Kidneys Could Boost Transplants, Improve Equity, With Matthew Kaufmann, PhD

Resilience, Rejection, and Recognition in Academic Dermatology

Race-Neutral Spirometry Gains Support as Standard Practice, With Nicole Ramsey, MD, PhD

FDA Issues Third Reproxalap CRL for Dry Eye Disease